Feb 12 (Reuters) - Abbvie ABBV.N:
ABBVIE AND XILIO THERAPEUTICS ANNOUNCE COLLABORATION AND OPTION AGREEMENT TO DEVELOP NOVEL TUMOR-ACTIVATED IMMUNOTHERAPIES
ABBVIE INC - COLLABORATION TO DEVELOP MASKED T-CELL ENGAGERS
ABBVIE INC - XILIO TO RECEIVE $52 MILLION UPFRONT, ELIGIBLE FOR UP TO $2.1 BILLION
Source text: ID:nPn9Fv6m9a
Further company coverage: ABBV.N